Dynamic Advisor Solutions LLC Has $8.70 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Dynamic Advisor Solutions LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,928 shares of the medical research company's stock after purchasing an additional 1,591 shares during the quarter. Dynamic Advisor Solutions LLC's holdings in Amgen were worth $8,701,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Centricity Wealth Management LLC acquired a new position in shares of Amgen during the 4th quarter worth approximately $25,000. Pinney & Scofield Inc. acquired a new position in shares of Amgen during the 4th quarter worth approximately $26,000. Ritter Daniher Financial Advisory LLC DE increased its holdings in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new position in Amgen in the 4th quarter valued at $34,000. Finally, Atala Financial Inc acquired a new position in Amgen in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Trading Down 0.7%

Amgen stock traded down $2.07 during trading hours on Friday, hitting $295.22. The stock had a trading volume of 2,191,182 shares, compared to its average volume of 2,820,660. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock has a market cap of $158.74 billion, a price-to-earnings ratio of 39.10, a P/E/G ratio of 2.63 and a beta of 0.51. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The business's 50 day simple moving average is $281.33 and its 200-day simple moving average is $285.62.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the company earned $3.96 earnings per share. The firm's revenue was up 9.4% compared to the same quarter last year. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.76% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have commented on AMGN shares. Johnson Rice set a $294.00 price objective on Amgen in a report on Wednesday, March 5th. Mizuho upped their price objective on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. UBS Group reaffirmed a "neutral" rating and issued a $315.00 price objective (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Guggenheim started coverage on Amgen in a report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective on the stock. Finally, Erste Group Bank lowered Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.